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The promyelocytic leukemia zinc finger (PLZF) tran-
scription factor is directly implicated in tumor suppression 
although the relevant target genes remain poorly defined. 
Shi et al. now implicate smooth muscle α-actin and changes 
in cytoskeletal architecture as key downstream targets of 
PLZF in opposing cellular transformation.
PLZF  is  a  transcriptional  repressor  belonging  to  the 
POZ-Krüppel (POK) family of transcription factors with 
critical roles in oncogenesis, development and stem cell 
maintenance  [1-7]. The  amino-terminal  POZ  domain  of 
PLZF  recruits  transcriptional  co-repressors  and  histone 
deacetylase  (HDAC)  activity  while  carboxy-terminal 
Krüppel-type zinc fingers mediate sequence-specific bind-
ing to gene promoter elements; leading to stable repression 
of relevant target genes [8, 9]. PLZF was originally identi-
fied from its involvement in chromosomal translocations 
with the RARA gene in cases of t(11;17) acute promy-
elocytic leukemia (APL) [10]. Expression of the result-
ing PLZF-RARα and RARα-PLZF fusion proteins drives 
acute leukemia development by disrupting expression of 
both  RARα  and  PLZF  target  genes  [5,  11-13].  RARα-
PLZF retains DNA binding domains of PLZF but replaces 
the POZ domain with a transactivating domain from RARα 
resulting in activation rather than repression of PLZF target 
genes. Therefore, abrogation of PLZF function and mis-
expression of PLZF target genes are thought to be critical 
for APL development [5]. Consistent with its role in APL, 
PLZF expression is associated with growth inhibition and 
cell cycle arrest through its ability to repress expression of 
a number of growth promoting and proto-oncogenic genes 
[14-16].
Subsequent to its original characterization in the con-
text of leukemia development, tumor suppressive functions 
have been attributed to PLZF in other cell types and tissues 
[17-19]. Using chicken embryonic fibroblasts (CEFs) as a 
model cell system, Shi et al. have previously demonstrated 
that PLZF opposes the transformation activity of a variety 
of cellular and viral oncogenes [20]. In terms of mechanism, 
the ability of PLZF to inhibit c-Myc function was associated 
with generation of this transformation-refractory state. In 
this issue, Shi et al. characterize smooth muscle α-actin as 
a novel PLZF target gene and link Ras-dependent changes 
in cytoskeletal architecture to PLZF-mediated inhibition 
of transformation. This novel mechanism thus represents 
an additional pathway by which PLZF is able to exert its 
tumor suppressive function (Figure 1). 
Commentary
Fig. 1.  Pathways of Plzf-mediated tumor suppression
PLZF can oppose cellular transformation through multiple 
targets. PLZF expression in CEFs leads to repression of 
smooth  muscle  α-actin  expression  and  triggers  cells  to 
adopt a flattened, polygonal morphology distinct from the 
typical fibroblastic shape. This cell morphology is associ-
ated with resistance to transformation induced by multiple 
distinct oncogenes. PLZF also inhibits c-Myc activity by tran-
scriptional and post-translational mechanisms to oppose cell 
growth and transformation. Regulation of cytoskeletal archi-
tecture and c-Myc by PLZF can be relevant to leukemia-initi-
ating cell (LIC) function and stem cell maintenance.4 www.impactjournals.com/oncotarget/ OncoTarget, May 2010
Oncogenic  stimuli  that  drive  cellular  transformation 
often trigger an accompanying remodeling of the cytoskele-
ton that results in altered cell morphology and growth prop-
erties [21]. Furthermore, the ability of tumor cells to invade 
surrounding tissue and ultimately metastasize is affected 
by changes in cell migration involving dynamic alterations 
to the cytoskeletal network [22]. Shi et al. make the criti-
cal observation that expression of PLZF in CEFs induces 
a reorganization of the actin stress fiber component of the 
cytoskeleton and alters cell morphology from the typical 
spindle-shaped fibroblastic shape to a polygonal and flat-
tened one. This morphological change was associated with 
a direct repression of smooth muscle α-actin expression 
by PLZF, suggesting that PLZF affects the cytoskeleton 
through modulation of the levels of specific structural com-
ponents.  Furthermore,  expression  of  dominant  negative 
Ras (RasN17) blocked PLZF-mediated alterations to cell 
morphology indicating involvement of small GTPases such 
as Ras, Rac and Rho in this cytoskeletal rearrangement. 
Importantly, the ability of PLZF to affect cell morphology 
was linked to its ability to oppose the generation of trans-
formed cell foci by distinct cellular and viral oncogenes; 
those  oncogenes  unable  to  revert  the  flattened,  polygo-
nal phenotype of PLZF-expressing CEFs (e.g. myr-Akt, 
c-Myc) were successfully opposed by PLZF while those 
oncogenes that reverted the PLZF-induced cellular mor-
phological changes (e.g. v-Src, v-Jun) did not have their 
transformation capabilities blocked by PLZF. These results 
thus define a connection between PLZF-induced changes 
to  cytoskeletal  architecture  and  PLZF  tumor  suppressor 
activity while underscoring the importance of cytoskeleton 
remodeling in oncogene-driven cellular transformation.
Taken together, these results offer important insight into the 
role of PLZF in opposing oncogenesis and raise a number 
of interesting questions warranting further investigation. 
Namely, how do PLZF-mediated changes to the actin cyto-
skeleton inhibit transformation and what are the relevant 
mechanisms by which certain oncogenes circumvent this? 
In addition, can this PLZF-driven cytoskeletal remodeling 
be translated into the context of tumor development where 
drastic alterations to the cytoskeleton occur, such as during 
epithelial-to-mesenchymal  transition  (EMT)  and  cancer 
cell invasion? Furthermore, while smooth muscle α-actin is 
identified as a direct target of PLZF, it remains to be shown 
whether reduced expression of this gene is entirely respon-
sible for observed changes to the CEF actin cytoskeleton 
upon PLZF expression. The potential existence of alterna-
tive PLZF target genes involved in cytoskeleton remodel-
ing could extend this model of tumor suppression to other 
cell types where smooth muscle α-actin is not typically 
expressed. In addition, given the ability of PLZF to oppose 
c-Myc function at multiple levels in these CEF transforma-
tion assays, it will be interesting to assess potential cross-
talk between c-Myc, smooth muscle α-actin expression and 
cellular transformation. Finally, these studies can provide 
insight and raise new questions regarding the role of PLZF 
in both leukemia development and stem cell maintenance 
[2-5, 7]; do the fusion proteins of t(11;17) APL drive leu-
kemogenesis  in  part,  through  opposing  PLZF-regulated 
cytoskeletal architecture and does this mechanism of PLZF 
action have a role in stem cell biology?
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